Autosomal dominant axonal Charcot-Marie-Tooth disease type 2N (CMT2N) is a very rare, inherited nerve disease. It mainly damages the long “wires” of the nerves (called axons) in the arms and legs. Because the nerves are weak, the muscles they supply slowly become weak and thin, and feeling (sensation) in the feet and hands can decrease. This condition usually progresses slowly over many years.Genetic & Rare Diseases Center+2Orpha+2
Autosomal dominant axonal Charcot-Marie-Tooth disease type 2N (often shortened to CMT2N) is a rare, mild form of Charcot-Marie-Tooth (CMT) disease. It is a genetic nerve disease that mainly damages the long nerves to the feet and hands (peripheral sensorimotor neuropathy). People usually develop weakness and wasting of the lower leg muscles, loss of feeling in the feet, foot drop, and high-arched feet (pes cavus), and symptoms usually get worse slowly over many years. Genetic & Rare Diseases Center+1
CMT2N is “autosomal dominant,” which means the faulty gene is on one of the numbered (non-sex) chromosomes, and a person only needs one changed copy of that gene from either parent to be affected. Each child of an affected parent has about a 50% chance of inheriting the disease. CMT2N has been linked to pathogenic variants in the AARS gene, which affects how nerve cells make and use proteins and can injure the axon, the long “wire-like” part of the nerve. Genetic & Rare Diseases Center+2PMC+2
“Autosomal dominant” means a person can get the disease when they inherit one changed copy of the gene from either their mother or their father. Each child of an affected parent has a 1 in 2 (50%) chance to inherit the changed gene.Orpha+1
“Axonal type 2” means this form of Charcot-Marie-Tooth (CMT) belongs to the CMT2 group. In this group, the main problem is damage to the nerve axon itself, not to the myelin covering. Nerve conduction studies show low signal strength (amplitude) with normal or slightly slow speed.PMC+2Europe PMC+2
Type 2N is most often caused by harmful changes (mutations) in a gene called AARS1 (alanyl-tRNA synthetase 1). This gene helps cells build proteins correctly. When the gene does not work properly, long motor and sensory nerves are especially sensitive and can slowly degenerate.PubMed+2PMC+2
Other names
Doctors and databases use several other names for this same disease. All of the names below refer to autosomal dominant axonal CMT type 2N:MalaCards+2NCBI+2
Charcot-Marie-Tooth disease, axonal, type 2N
Charcot-Marie-Tooth disease axonal type 2N
CMT2N
Autosomal dominant Charcot-Marie-Tooth disease type 2N
Charcot-Marie-Tooth neuropathy type 2N
Charcot-Marie-Tooth neuropathy, axonal, type 2N
Autosomal dominant axonal Charcot-Marie-Tooth disease type 2N
Charcot-Marie-Tooth disease, axonal, autosomal dominant, type 2N
AARS Charcot-Marie-Tooth disease type 2
Charcot-Marie-Tooth disease type 2 caused by mutation in AARS
All of these names point to the same clinical picture: a mild to moderate, slowly progressive axonal neuropathy affecting motor and sensory nerves in the limbs.Orpha+2National Organization for Rare Disorders+2
Types
There is only one official genetic subtype called “type 2N,” but doctors may still describe patients in informal “types” based on how the disease looks in real life. These are not official genetic subtypes; they are only clinical patterns:Orpha+2CMT Research Foundation+2
Childhood-onset CMT2N – symptoms (such as tripping, foot drop, or high-arched feet) start in childhood or teenage years. Weakness tends to be present for many years but progresses slowly.
Adult-onset CMT2N – symptoms first show in early or middle adult life. People may notice ankle weakness, numb toes, or difficulty running. Progression is still slow, but the person may already have long nerves under age-related stress when the illness appears.
Mild CMT2N – some people have only very slight weakness or sensory loss, and they may remain almost symptom-free for many years. In some families, a few carriers have abnormal genetic results but normal nerve tests and almost no complaints.Charcot-Marie-Tooth Association+1
Moderate CMT2N – others have clear weakness in the feet and later in the hands. They may show visible muscle thinning and clear sensory loss, but often remain able to walk and work with some adaptations.pfmjournal.org+1
Motor-predominant CMT2N – in some people, muscle weakness and wasting are much more obvious than loss of feeling. These patients are sometimes described as having “distal hereditary motor neuropathy” but share the same AARS1 gene problem.American Academy of Neurology+1
Sensory-motor CMT2N – many patients have both weakness and sensory loss. They feel numbness, tingling, or burning pain in addition to muscle problems.Genetic & Rare Diseases Center+1
Asymmetric CMT2N – in some families, one leg or one side is more affected than the other, especially in early phases. Over time, both sides usually become involved.Genetic & Rare Diseases Center+1
Causes
Important note: For CMT2N there is one main root cause: a harmful change (mutation) in the AARS1 gene. The 20 “causes” below explain this main cause from different angles and describe factors that can influence how the disease appears or how severe it becomes.PubMed+2PMC+2
Harmful mutation in the AARS1 gene
The primary cause of CMT2N is a pathogenic mutation in the AARS1 gene, which encodes the enzyme alanyl-tRNA synthetase 1. This enzyme is needed in every cell to attach the amino acid alanine to its tRNA during protein building. When the gene is mutated, the enzyme does not work normally, and long peripheral nerves become vulnerable to damage.PubMed+2PMC+2Autosomal dominant inheritance from an affected parent
Most people with CMT2N inherit the mutated AARS1 gene from an affected mother or father. Because the condition is autosomal dominant, one faulty gene copy is enough to cause the disease, and each child has a 50% chance to inherit it.Orpha+2NCBI+2New (de novo) mutation in AARS1
Sometimes the mutation appears for the first time in a child, even though both parents have normal genes. This is called a de novo mutation. The child can later pass the mutated gene on to their own children in an autosomal dominant way.The Company of Biologists+1Missense changes in key regions of the enzyme
Many reported AARS1 mutations are “missense” changes, where one amino acid in the enzyme is replaced by another. If the changed amino acid lies in a critical region that binds alanine or tRNA, the enzyme may lose accuracy or stability, leading to nerve damage.MalaCards+2ScienceDirect+2Loss-of-function or hypomorphic effect
Some variants make the enzyme work much less well (loss-of-function) or only partially (hypomorphic). When protein building is inefficient, especially in long axons, the nerves may not maintain their structure and slowly degenerate.The Company of Biologists+1Dominant-negative or toxic gain-of-function effect
In some autosomal dominant diseases, the mutated protein not only loses its normal job but also interferes with the normal copy or gains a toxic function. For AARS1, research suggests that some mutations may mis-interact with other cell pathways and stress the neuron.ScienceDirect+2ScienceDirect+2Selective vulnerability of long motor axons
The axons to the feet and hands are very long, so they are especially sensitive to problems in protein supply and axonal transport. As a result, these nerves are damaged first and most strongly when AARS1 cannot support normal protein building.PMC+2pfmjournal.org+2Selective vulnerability of long sensory axons
Long sensory fibers that carry feeling from the feet and hands also depend on healthy protein production and transport. They are weakened by the same mutation, causing sensory loss and neuropathic pain in many patients.Genetic & Rare Diseases Center+2pfmjournal.org+2Axonal degeneration due to impaired protein quality control
Aminoacyl-tRNA synthetases (like AARS1) also have roles in cell stress responses. When these roles are disturbed, misfolded proteins may build up in axons and trigger chronic damage and degeneration.ScienceDirect+1Disturbed axonal transport
Long axons need efficient transport of proteins and organelles along microtubules. CMT2 in general has been linked to genes that disturb axonal transport, and AARS1 dysfunction may indirectly disturb this process, contributing to axon loss.balkanmedicaljournal.org+2MalaCards+2Mitochondrial stress and energy imbalance
Neurons need much energy to maintain axons. Abnormal protein handling caused by AARS1 mutations may strain mitochondria and energy production, so axons cannot maintain their membranes and slowly die back from the ends.PMC+1Interaction with other nerve genes (genetic modifiers)
Some people with the same AARS1 mutation are more severely affected than others. This difference may be partly due to extra variants in other nerve-related genes (such as neurofilament or heat-shock protein genes) that modify disease severity.balkanmedicaljournal.org+2MalaCards+2Age-related axonal wear and tear
As people age, axons naturally become more vulnerable. In someone who already has a harmful AARS1 mutation, normal aging may speed up the appearance and progression of symptoms.CMT Research Foundation+1Possible metabolic triggers (illness, poor control of diabetes, etc.)
While they do not cause CMT2N, extra metabolic stresses such as poorly controlled diabetes or severe nutritional lack can further harm already fragile nerves and make symptoms worse.PMC+2Mayo Clinic+2Mechanical stress on weakened ankles and feet
Repeated sprains, long-standing, or heavy physical load on weak ankles can worsen nerve irritation and muscle imbalance. This is not a root cause but a factor that can worsen foot deformities and symptoms.Muscular Dystrophy Association+1Secondary muscle atrophy from denervation
Nerves that are slowly damaged send fewer signals to muscles. Over time, this leads to muscle wasting and weakness, especially in the calves and intrinsic foot muscles. This atrophy is a consequence of the nerve disease but further limits function.pfmjournal.org+2Orthobullets+2Development of foot deformities (pes cavus, hammertoes)
Imbalance between weak and relatively strong muscles around the foot and ankle gradually pulls the bones into high arches and curled toes. These deformities increase local pressure and make walking harder, worsening disability.Muscular Dystrophy Association+2Mayo Clinic+2Reduced tendon reflexes and loss of protective feedback
Damaged axons lead to reduced knee reflexes and absent ankle reflexes. Without these protective responses, the joints can suffer unbalanced load and instability, which may cause more sprains and falls.Genetic & Rare Diseases Center+2NCBI+2Delayed diagnosis and lack of early support
If diagnosis is delayed, people may walk for years without proper orthotic support or physiotherapy. This allows more contractures, stiffness, and falls, turning a mild genetic neuropathy into a more disabling state.Orthobullets+2CMT Research Foundation+2Family and reproductive transmission over generations
Because the condition is autosomal dominant and usually compatible with long life, the mutation can pass through many generations. This genetic transmission is the deep reason why CMT2N continues to appear in family trees.Orpha+2NCBI+2
Symptoms
Weakness in the feet and ankles
One of the earliest and most common symptoms is weakness in the muscles that lift the front of the foot. People may have trouble keeping the toes up, leading to “foot drop” and difficulty running or climbing stairs.Muscular Dystrophy Association+2Mayo Clinic+2Frequent tripping and falls
Because the toes drag and the ankle is unstable, people often trip on small obstacles or uneven ground. This can lead to repeated sprains, cuts, or fractures.Muscular Dystrophy Association+1High-arched feet (pes cavus)
Many patients develop high arches as some muscles weaken and others remain relatively strong. The strong muscles pull the foot into an abnormal high-arched shape. This can cause pain, calluses, and difficulty finding comfortable shoes.Muscular Dystrophy Association+2Mayo Clinic+2Curled toes (hammertoes)
Toe muscles become imbalanced and can no longer keep the toes straight. The toes may curl downward or upward, causing calluses, rubbing, and pain, especially in tight shoes.Mayo Clinic+2National Organization for Rare Disorders+2Visible thinning of lower leg muscles
Over time, the calf muscles become thin because they are not fully activated by the nerves. The legs may look like an “inverted champagne bottle,” with thin calves and relatively normal thighs.Muscular Dystrophy Association+2Mayo Clinic+2Weakness in the hands and fingers
As the disease progresses, the small muscles of the hands can also be affected. People may notice they drop objects, struggle with buttons, or find handwriting more difficult.Orpha+2National Organization for Rare Disorders+2Numbness in feet and toes
Many people feel a loss of normal sensation in the feet, starting with the toes. They may not feel light touch, pain, or temperature as well as before, making them more prone to unnoticed injuries.Genetic & Rare Diseases Center+2Mayo Clinic+2Pins and needles or burning pain
Damaged sensory nerves can send abnormal signals. People may feel tingling, pins and needles, or burning pain in their feet, even without injury. This is called neuropathic pain.Mayo Clinic+1Reduced balance and unsteady walking
Loss of joint-position sense and muscle weakness make balance difficult. People may sway more, especially in the dark or when standing on soft ground, and feel unsteady when walking.Muscular Dystrophy Association+2Orthobullets+2Reduced or absent ankle reflexes
When the doctor taps the Achilles tendon, the normal ankle jerk is weak or absent. Knee reflexes are often reduced. Patients do not notice this directly, but it is a classic examination finding.Genetic & Rare Diseases Center+2NCBI+2Tiredness after walking or standing
Because the muscles are weak and must work harder, even short walks or long standing can cause fatigue and aching in the legs.CMT Research Foundation+1Difficulty running or jumping
Running and jumping require strong ankle and foot muscles. Many people with CMT2N cannot run as fast as peers and may stop participating in impact sports.Muscular Dystrophy Association+2Mayo Clinic+2Hand clumsiness with fine tasks
When hand muscles are involved, tasks like using keys, handling small coins, or doing crafts become harder. People may adapt by using assistive tools.Europe PMC+1Slow and variable progression
The disease usually progresses slowly over many years. In some family members it may remain very mild, while in others it becomes more obvious. This variability is typical of CMT2N.Genetic & Rare Diseases Center+2Orpha+2Emotional and social impact
Repeated sprains, visible leg changes, or the need for braces can affect self-confidence, work choices, and social activities. Emotional support and counselling may be helpful, even though the primary problem is neurological.CMT Research Foundation+1
Diagnostic tests
Physical exam tests
General neurological examination
The doctor studies muscle strength, tone, reflexes, and sensation in all four limbs. In CMT2N, they often find distal weakness (farther from the trunk), reduced or absent ankle reflexes, and a “stocking” pattern of sensory loss in the feet.Genetic & Rare Diseases Center+2pfmjournal.org+2Observation of gait (walking pattern)
The clinician watches the patient walk and run if possible. A high-steppage gait, where the person lifts the knees higher to clear the toes, suggests foot drop from distal weakness, as commonly seen in CMT2.Muscular Dystrophy Association+2Orthobullets+2Inspection of feet and legs
The doctor looks for high arches, hammertoes, calluses, ankle swelling, and visible muscle wasting. Characteristic deformities strongly support a diagnosis of CMT-type neuropathy.Muscular Dystrophy Association+2Mayo Clinic+2Balance testing (Romberg and tandem gait)
The patient is asked to stand with feet together and eyes closed, or to walk heel-to-toe in a straight line. Increased swaying or unsteady tandem gait suggest loss of proprioception and distal muscle weakness.Orthobullets+2CMT Research Foundation+2
Manual bedside tests
Manual muscle testing with strength grading
The examiner tests key muscle groups (ankle dorsiflexion, plantarflexion, toe extension, hand grip) against resistance and grades them from 0 to 5. In CMT2N, distal muscle groups are weaker than proximal ones.pfmjournal.org+2Orthobullets+2Sensory testing with cotton, pin, and temperature
Light touch, pinprick, and temperature are checked in the feet, legs, hands, and arms using simple tools. Reduced sensation in a stocking-glove pattern is typical of length-dependent peripheral neuropathy.Genetic & Rare Diseases Center+2Mayo Clinic+2Vibration and joint-position testing
A tuning fork is placed over bony points, and the patient is asked to feel the vibration. The doctor also moves toes up or down and asks the patient which way they moved. Loss of these senses points to large-fiber sensory nerve involvement.Orthobullets+2pfmjournal.org+2Deep tendon reflex testing
Using a reflex hammer, the doctor tests knee and ankle jerks. In CMT2N, ankle reflexes are often absent and knee reflexes reduced, supporting a peripheral neuropathy with axonal loss.Genetic & Rare Diseases Center+2NCBI+2Functional tests such as heel-walk and toe-walk
Patients are asked to walk on heels and then on toes. Difficulty walking on heels suggests weakness of ankle dorsiflexors, which is a common early sign of CMT2.Muscular Dystrophy Association+2Orthobullets+2
Lab and pathological tests
Routine blood tests to rule out other neuropathies
Tests such as fasting glucose, vitamin B12, thyroid function, kidney and liver tests, and serum protein electrophoresis help exclude acquired causes of neuropathy (like diabetes or vitamin deficiency). Normal results support a hereditary cause like CMT2N.PMC+2Mayo Clinic+2Genetic testing panel for CMT
Many centers use next-generation sequencing panels that include dozens of neuropathy genes. These panels often contain AARS1 and can detect mutations linked with CMT2N, helping confirm the diagnosis at the DNA level.MalaCards+2NCBI+2Targeted AARS1 gene sequencing
If CMT2N is strongly suspected, direct sequencing of the AARS1 gene can identify the specific mutation. This is valuable for confirming the diagnosis and for family counselling.PubMed+2ResearchGate+2Segregation analysis in family members
When a variant is found, testing other affected and unaffected relatives helps show whether the variant tracks with the disease in the family. This supports its classification as a disease-causing mutation.PubMed+2PMC+2Nerve biopsy (rarely used now)
In unclear cases, a small piece of peripheral nerve (often sural nerve) may be examined under the microscope. In axonal CMT2, biopsy shows axonal degeneration with relatively preserved myelin, confirming axonal neuropathy, although genetic testing has largely replaced this invasive test.PMC+2Europe PMC+2
Electrodiagnostic tests
Nerve conduction studies (NCS)
Electrodes stimulate nerves and record responses. In CMT2N and other axonal CMT2 types, amplitudes (signal size) are reduced, while conduction velocities are normal or only slightly slowed. This pattern indicates primary axonal damage rather than demyelination.PMC+2Europe PMC+2Electromyography (EMG)
A fine needle electrode is inserted into muscles to record electrical activity. EMG in CMT2N shows chronic denervation and re-innervation, confirming a long-standing neurogenic process rather than a primary muscle disease.PMC+2pfmjournal.org+2F-wave and H-reflex studies
These special nerve conduction responses test the entire length of the motor neuron and reflex arcs. Reduced or absent responses support peripheral nerve involvement and may reveal subclinical changes even when standard studies are borderline.PMC+1Quantitative sensory testing (QST)
QST uses controlled stimuli (vibration, temperature) and patient responses to measure sensory thresholds. It can document small and large fiber sensory loss and help track changes over time in CMT patients.pfmjournal.org+1
Imaging tests
Foot and ankle X-rays
X-rays of the feet and ankles show bone alignment, high arches, hammertoes, and joint damage. They do not show nerve damage directly but are useful for planning orthopedic treatment and for documenting deformities caused by the neuropathy.Orthobullets+1MRI or ultrasound of peripheral nerves and spine
MRI of the spine and nerve roots can exclude other causes of neuropathy, such as spinal cord compression. High-resolution ultrasound or MR neurography may show thinning of distal nerves in hereditary axonal neuropathies, although this is more a research tool. Imaging is mainly used to rule out other conditions, not to directly diagnose CMT2N.PMC+2pfmjournal.org+2
Non-pharmacological treatments (therapies and other approaches)
Physiotherapy (strength and endurance training)
Regular, supervised physiotherapy helps keep leg and core muscles as strong as possible, slows contractures (joint stiffness), and improves walking pattern. Simple exercises like repeated heel raises (if possible), hip strengthening, and low-impact aerobic work (cycling, swimming, walking in water) are commonly used. The goal is not to “push through” weakness, but to train gently, several times per week, so muscles work efficiently without over-fatigue or injury. ScienceDirect+2nhs.uk+2
Balance and gait (walking) training
Many people with CMT2N trip or feel unsteady because of foot drop and loss of position sense. Physiotherapists use simple balance tasks (standing with feet together, walking on different surfaces, step training) and teach compensating strategies such as high-stepping gait or turning carefully. This type of training can reduce falls and improve confidence, especially when combined with braces or canes if needed. Wikipedia+2OrthoBullets+2
Stretching and contracture prevention
Tight calf muscles, hamstrings, and plantar fascia are common due to long-term muscle imbalance and abnormal foot posture. A daily home stretching plan for ankles, hamstrings, and toes helps keep joints mobile and can delay fixed deformities. Long, gentle stretches (20–30 seconds, several times) are safer than forceful bouncing. In advanced cases, night splints may hold the ankle in a more neutral position while sleeping. OrthoBullets+2Wikipedia+2
Orthotic devices and ankle-foot orthoses (AFOs)
Lightweight plastic or carbon AFOs can lift the front of the foot during swing phase and stop it from slapping the ground, which reduces tripping and makes walking safer and less tiring. Custom insoles and shoe modifications help redistribute pressure away from bony prominences in a cavus foot and can relieve pain under the forefoot or heel. Orthopaedic and podiatry guidelines for CMT and pes cavus strongly support early use of orthoses to prevent falls and ulcers. www.slideshare.net+2Wikipedia+2
Occupational therapy and hand therapy
Occupational therapists help with fine-motor problems in the hands, such as difficulty with buttons, zippers, writing, and phone use. They may suggest adaptive tools (built-up pen grips, button hooks, special keyboards) and exercises to maintain finger strength and flexibility. Hand splints or wrist supports can improve function and reduce fatigue during tasks like typing or cooking. ScienceDirect+2nhs.uk+2
Assistive devices and mobility aids
Simple devices like canes, trekking poles, or walkers can dramatically improve safety if balance is poor or the person has frequent falls. Physiotherapists teach the correct height and pattern of use so the aid supports, rather than disrupts, the gait. For longer distances, a manual or power wheelchair may preserve independence and allow participation in school, work, and community activities without exhausting the person. Wikipedia+2Charcot-Marie-Tooth Association+2
Home safety and fall-prevention changes
Removing loose rugs, installing grab bars and railings, improving lighting, and using non-slip mats in bathrooms can reduce serious injuries from falls. For someone with CMT, even a small fall can cause fractures because the ankle is unstable and the foot is deformed. Many neuropathy and CMT guidelines highlight home modification as a low-cost, high-impact intervention. nhs.uk+2OrthoBullets+2
Patient education, psychological support, and peer groups
Living with a visible disability and chronic pain can be emotionally difficult. Education about the genetic nature of CMT2N, realistic prognosis, and treatment options reduces fear and uncertainty. Support from patient organizations, such as CMT foundations and rare-disease groups, helps people connect, share tips, and learn about clinical trials and new research. Genetic & Rare Diseases Center+2CMT Research Foundation+2
Drug treatments (symptom-targeted medicines)
There is no medicine currently approved specifically to cure or slow autosomal dominant axonal CMT type 2N. Available drugs are used to treat symptoms like neuropathic pain, cramps, sleep disturbance, and mood changes. Most of these medicines are approved by the U.S. FDA for conditions such as diabetic neuropathic pain or other chronic pain states, and are sometimes used “off-label” in hereditary neuropathies like CMT according to neuropathic pain guidelines. Genetic & Rare Diseases Center+3Charcot-Marie-Tooth Association+3PubMed+3
All doses below are typical adult ranges from FDA-approved labels or major guidelines, not personal prescriptions. A neurologist must adjust doses based on age, kidney function, other medicines, and side-effects. FDA Access Data+2FDA Access Data+2
Pregabalin (Lyrica – anti-seizure/neuropathic pain drug)
Pregabalin binds to a calcium-channel subunit on nerve cells and reduces release of excitatory neurotransmitters, which calms over-active pain pathways. The FDA label approves pregabalin for neuropathic pain in diabetes, spinal cord injury, and post-herpetic neuralgia; some neurologists extrapolate this evidence to CMT-related neuropathic pain. Typical adult doses range from 150–600 mg per day in divided doses, starting low and increasing slowly to limit dizziness, drowsiness, weight gain, and ankle swelling. Charcot-Marie-Tooth Association+3FDA Access Data+3FDA Access Data+3
Gabapentin (Neurontin – anti-seizure/neuropathic pain drug)
Gabapentin is a related medicine that also targets calcium-channel subunits and reduces abnormal firing in pain fibres. It is widely used as a first-line drug for neuropathic pain, including hereditary neuropathies, despite not being specifically approved for CMT. Guidelines often start adults at 300 mg at night and gradually increase to 900–3600 mg per day in three divided doses, limited by dizziness, sleepiness, and weight gain. Charcot-Marie-Tooth Association+2PubMed+2
Duloxetine (Cymbalta – SNRI antidepressant)
Duloxetine blocks re-uptake of serotonin and noradrenaline in the spinal cord, which enhances natural pain-inhibiting pathways. The FDA label includes indications for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain, and studies show it can reduce burning, tingling, and all-day pain scores. Typical adult dose for neuropathic pain is 60 mg once daily, with nausea, dry mouth, sweating, and sleep changes as common side effects. Careful monitoring is needed in young people because all antidepressants can rarely increase suicidal thoughts. PMC+3FDA Access Data+3FDA Access Data+3
Tricyclic antidepressants (e.g., amitriptyline, nortriptyline)
Low-dose tricyclics block re-uptake of serotonin and noradrenaline and also act on sodium channels, making them effective and inexpensive neuropathic pain medicines. They are often taken at night (10–25 mg to start) because they cause sleepiness and dry mouth; doses are gradually raised if tolerated. In people with heart disease, glaucoma, or severe constipation, they must be used very carefully or avoided because of cardiac conduction effects and anticholinergic side-effects. Charcot-Marie-Tooth Association+2PubMed+2
Topical lidocaine (5% patches or gels)
Lidocaine patches can be placed over areas of focal burning pain (for example, the top of the foot) to numb the superficial nerves without causing whole-body side-effects. The FDA label approves 5% lidocaine patches for post-herpetic neuralgia, but neuropathy guidelines also support their use in other localized neuropathic pain states when systemic drugs are not tolerated. Typical use is up to 12 hours on, followed by 12 hours off, keeping to the maximum number of patches stated in the label. Charcot-Marie-Tooth Association+2PubMed+2
NSAIDs, paracetamol, and short-term tramadol (for musculoskeletal pain)
Neuropathic pain medicines do not always control pain from strained joints, tendon overuse, or back pain related to abnormal gait. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen, and paracetamol (acetaminophen), can help this “mechanical” pain, as described in peripheral neuropathy and CMT management reviews. In severe cases, tramadol or other weak opioids may be used short-term, but long-term opioids are usually avoided because they do not treat the underlying neuropathy and carry risks of dependence and side-effects. eMedicine+2ScienceDirect+2
Dietary molecular supplements (supportive, not curative)
No supplement has been proven to cure or clearly slow CMT2N, but some nutrients have been studied in peripheral neuropathy and nerve health. Evidence is mostly from diabetic neuropathy or CMT1A, and results are mixed, so supplements should always be discussed with a doctor. The Foundation for Peripheral Neuropathy+2Health+2
Alpha-lipoic acid (ALA)
ALA is an antioxidant that helps mop up damaging free radicals and may improve nerve blood flow. Randomized trials in diabetic neuropathy show that oral doses around 600 mg/day can modestly reduce burning and tingling pain, with more recent studies exploring safety and effectiveness alongside gabapentin or pregabalin. Common side-effects include nausea and stomach upset. There is no strong proof that ALA changes the course of CMT2N, but some doctors consider a monitored trial in adults with significant neuropathic pain. Cochrane Library+2Cureus+2
Omega-3 fatty acids (fish oil, algae oil)
Long-chain omega-3 fats (EPA and DHA) found in fatty fish and fish oil supplements help reduce inflammation and may support nerve regeneration. Human and animal studies suggest that several months of omega-3 supplementation can improve measures of nerve function and promote regrowth in some neuropathy models, though not specifically CMT2N. Typical doses used in studies are around 1–3 g/day of combined EPA/DHA, but higher doses should be supervised because of bleeding risk in people on blood thinners. Neurosurgery & Spine Consultants+3Diabetes Journals+3The Foundation for Peripheral Neuropathy+3
B-vitamin complexes, especially vitamin B12
B-vitamins (B1, B6, B9, B12) are essential for healthy nerve metabolism and myelin formation. Vitamin B12 deficiency alone can cause severe neuropathy and balance problems, which sometimes improve with replacement. Many neuropathy resources recommend checking B12 levels and using a B-complex supplement if intake is low, especially in people with vegetarian diets or stomach problems. Typical oral B12 doses for deficiency are much higher than the usual daily requirement and should be guided by a doctor. Neurosurgery & Spine Consultants+3Verywell Health+3EatingWell+3
Vitamin C (ascorbic acid)
Vitamin C is needed for collagen and myelin formation, and early animal work suggested that high-dose vitamin C might improve CMT1A. However, several controlled trials in people with CMT1A did not show meaningful clinical benefit, and current reviews do not recommend high-dose vitamin C as a disease-modifying treatment. Normal dietary intake (through fruits and vegetables) is still important for overall nerve and immune health. ScienceDirect+2Cochrane+2
Vitamin D and general micronutrient support
Low vitamin D levels are common and are linked with more pain and poorer nerve and muscle function in several conditions. Neuropathy nutrition resources recommend checking vitamin D and correcting deficiency, often with 800–2000 IU/day or higher short-term under medical supervision. Together with magnesium, antioxidants, and a healthy diet, vitamin D may support nerve repair even though it has not been specifically tested in CMT2N. Health+2Neurosurgery & Spine Consultants+2
Immune-booster, regenerative and stem-cell-related approaches
Right now, there is no approved immune-booster, regenerative drug, or stem cell product that has been proven safe and effective for autosomal dominant axonal CMT type 2N. However, research in CMT in general is moving quickly, especially in gene therapy and cell-based approaches. PMC+2Institut Myologie+2
Experimental mesenchymal stem-cell therapies such as EN001 have shown early signals of improved strength and remyelination in CMT1A models and small human trials, and some countries have approved phase 1/2 studies in people with CMT. These treatments attempt to release growth factors, calm inflammation, and support Schwann cells, but long-term safety and effectiveness are still unknown. ScienceDirect+3Charcot-Marie-Tooth News+3Charcot-Marie-Tooth Association+3
Several gene-therapy projects aim to silence over-expressed genes or replace missing ones in specific CMT subtypes, such as CMT4C, CMT2S and others. These use viral or plasmid vectors to deliver corrected genes to nerve or Schwann cells. Although they do not yet target CMT2N specifically, progress in related subtypes may open the door to future AARS-focused therapies. For now, these treatments are only available within strict clinical trials at specialized centres. CMT Research Foundation+4CMT Research Foundation+4PMC+4
Because many rare-disease “stem-cell” or “immune-boosting” products sold online are unregulated and risky, families are strongly advised to only consider therapies that are part of registered clinical trials and to discuss them with recognized CMT experts before travelling or paying large sums. Walsh Medical Media+2PMC+2
Surgical options
Surgery is not needed for everyone with CMT2N, but can help when cavovarus feet, hammertoes, or ankle instability cause severe pain, frequent falls, or make it impossible to wear shoes. The general aim is to rebalance muscles, correct deformity, and create a plantigrade (flat-on-the-ground) foot that works better with or without braces. OrthoBullets+3PubMed+3PubMed+3
Tendon transfer procedures (e.g., Jones procedure, tibialis posterior transfer)
In tendon transfer surgery, a stronger muscle’s tendon is moved so it can help a weaker movement, such as lifting the foot. For example, the extensor hallucis longus tendon can be rerouted to help dorsiflex the first metatarsal (Jones procedure), or the tibialis posterior can be transferred to the front of the ankle to reduce foot drop. This helps rebalance the foot and can improve walking and brace use. PubMed+2PubMed+2
Osteotomy and soft-tissue releases for cavovarus foot
In cavovarus surgery, the surgeon may cut and reposition bones (osteotomies) of the midfoot, first metatarsal, or calcaneus, and release tight structures like the plantar fascia. These procedures aim to lower very high arches, correct heel varus, and straighten clawed toes, often as part of a “triple surgery” or staged reconstruction plan. Studies show that careful reconstruction can improve function and pain while preserving as much joint movement as possible. AAOS+3PubMed+3www.elsevier.com+3
Fusion (arthrodesis) in severe, rigid deformity or arthritis
If joints are severely deformed, unstable, or arthritic, surgeons may fuse (join) some of them so the foot becomes stiff but more stable and less painful. Examples include triple arthrodesis of the hindfoot. Fusion is usually considered only after joint-sparing procedures have failed or are not possible, especially in older patients with long-standing deformity. Lower Extremity+2Journal of the Foot & Ankle+2
Decisions about timing and type of surgery are complex and should be made in a centre with experience in CMT foot surgery.
Prevention and lifestyle strategies
While CMT2N itself cannot currently be prevented, you can lower the risk of complications and keep nerves and muscles as healthy as possible:
Stay physically active in a safe way – gentle regular activity helps maintain muscle bulk, joint mobility, and cardiovascular health without over-straining weak muscles. ScienceDirect+2Blue Ridge Acupuncture+2
Avoid neurotoxic medicines where possible – some chemotherapy drugs (like vincristine) and high-dose alcohol can worsen neuropathy; doctors usually try to avoid these in people with known CMT unless absolutely necessary. ScienceDirect+2Wikipedia+2
Protect your feet every day – inspect skin for blisters, calluses, or cuts, wear cushioned socks and well-fitting shoes, and see a podiatrist early for pressure points to avoid ulcers. Wikipedia+2OrthoBullets+2
Keep a healthy body weight and manage blood sugar – excess weight and diabetes both add strain to already weak nerves and joints and can accelerate neuropathy. The Foundation for Peripheral Neuropathy+2Cleveland Pain Specialists+2
Avoid smoking and limit or avoid alcohol – smoking reduces blood flow to nerves, and alcohol can directly injure peripheral nerves; neuropathy resources strongly advise cutting both where possible. The Foundation for Peripheral Neuropathy+2Cleveland Pain Specialists+2
Keep vaccinations up to date – infections that cause high fever, pneumonia, or prolonged bed rest can worsen weakness and balance; standard vaccines (flu, COVID-19, pneumonia) are generally recommended unless your doctor advises otherwise. Genetic & Rare Diseases Center+2ScienceDirect+2
What to eat and what to avoid
No single “CMT2N diet” exists, but a Mediterranean-style, whole-food diet seems helpful for nerve, heart, and brain health. This diet focuses on vegetables, fruits, whole grains, legumes, nuts, seeds, olive oil, and fish, with limited red meat, sugar, and ultra-processed foods. It is naturally anti-inflammatory and rich in antioxidants, which may support nerve repair and reduce chronic pain. Wikipedia+3The Foundation for Peripheral Neuropathy+3Blue Ridge Acupuncture+3
Good daily choices include:
Plenty of colorful fruits and vegetables (berries, citrus, leafy greens, tomatoes, peppers) for vitamins C, E, folate, and antioxidants. The Foundation for Peripheral Neuropathy+2theshifttc.com+2
Whole grains such as oats, brown rice, and quinoa instead of white bread or sugary cereals to keep blood sugar stable and reduce inflammation. The Foundation for Peripheral Neuropathy+2Cleveland Pain Specialists+2
Lean proteins like fish, skinless poultry, beans, and lentils to provide essential amino acids and B-vitamins without excess saturated fat. Fatty fish (salmon, sardines, mackerel) also supply omega-3s that support nerve and brain health. advancedreconstruction.com+2Lone Star Neurology+2
Nuts and seeds (walnuts, almonds, flaxseed, chia) and olive oil as main fat sources to add magnesium, vitamin E, and healthy unsaturated fats. Wikipedia+3The Foundation for Peripheral Neuropathy+3YouTube+3
Try to avoid or limit:
Sugary drinks, sweets, and refined carbohydrates, which can worsen blood sugar swings and inflammation. NIVA Health+3The Foundation for Peripheral Neuropathy+3theshifttc.com+3
Ultra-processed snacks, deep-fried foods, and very salty fast food, which add calories but few nutrients and may increase pain and fatigue. enhance-center.com+2National Geographic+2
Alcohol, especially in large amounts, because it can directly damage peripheral nerves and interact with many neuropathic pain medicines. The Foundation for Peripheral Neuropathy+2Cleveland Pain Specialists+2
A dietitian experienced in neuromuscular disease can help build a detailed eating plan that fits culture, budget, and any other medical conditions.
When to see doctors
You should see a doctor (ideally a neurologist who knows about CMT) if you or a family member notice:
New or slowly increasing weakness in the feet or hands
High-arched feet, claw toes, or frequent ankle sprains
Numbness, tingling, burning pain, or loss of balance
Family history of CMT or unexplained neuropathy
Because CMT2N is genetic and slowly progressive, regular follow-up is important even when symptoms seem stable. Clinical guidelines recommend ongoing review to adjust braces, update therapy programmes, check for new complications (such as scoliosis or respiratory issues), and discuss research or clinical trials. CMT Research Foundation+3Genetic & Rare Diseases Center+3eMedicine+3
Seek urgent medical help if there is sudden severe weakness, rapid worsening of walking, new breathing difficulty, or serious injury from a fall. These may signal a complication that needs immediate care. Wikipedia+1
Frequently asked questions (FAQs)
1. Is autosomal dominant axonal CMT type 2N curable?
No. At present there is no cure or disease-modifying medicine for CMT2N. Treatment focuses on rehabilitation, orthotics, pain control, and sometimes surgery to keep you as active and independent as possible while research continues on gene and stem-cell therapies. Genetic & Rare Diseases Center+2Wikipedia+2
2. Will CMT2N shorten my life?
Most sources describe CMT2N as a mild, slowly progressive neuropathy. Many people live a normal life span, especially with good management of falls, foot problems, and general health. Quality of life can be improved with early rehabilitation and support. Genetic & Rare Diseases Center+2Wikipedia+2
3. Can children or teenagers get CMT2N?
Yes. Symptoms can begin at any age, from childhood to older adulthood. Early signs may include frequent tripping, clumsiness, or trouble keeping up in sports. If there is a family history or clear symptoms, a neurologist may suggest nerve tests and genetic testing. Genetic & Rare Diseases Center+1
4. Is it safe to exercise with CMT2N?
In general, gentle, regular exercise is recommended and considered safe when supervised. The key is to avoid over-fatigue, high-impact jumping, or heavy strength work that could injure weak muscles or unstable joints. A physiotherapist can design a personal programme. ScienceDirect+2OrthoBullets+2
5. Can CMT2N affect my hands or hearing?
Although leg and foot symptoms are most common, CMT2N can also involve the hands and, in some people, sensorineural hearing loss. This can make fine movements and communication more difficult, so regular hearing checks and early occupational therapy are helpful. Genetic & Rare Diseases Center+1
6. Should my family members be tested?
Because CMT2N is autosomal dominant, first-degree relatives (parents, siblings, children) have a higher chance of carrying the gene variant. Genetic counselling can explain pros and cons of testing, discuss family planning, and help relatives decide whether they want a genetic test. Genetic & Rare Diseases Center+2Wikipedia+2
7. Are stem-cell or gene therapies available now for CMT2N?
Several early-phase trials are exploring stem-cell therapy and gene therapy for some CMT types, but they are still experimental and are not yet standard treatment. For CMT2N specifically, no approved gene or stem-cell therapy exists, so any offers outside regulated clinical trials should be viewed very cautiously. CMT Research Foundation+3Charcot-Marie-Tooth News+3PMC+3
8. What is the most important thing I can do today?
The most powerful steps are often simple: build a trusted care team, keep moving with safe exercise, protect your feet, use braces or aids if recommended, follow a nerve-healthy diet, and look after your mental health. These actions will not remove the genetic cause, but they can greatly improve comfort, independence, and long-term outcomes while research progresses. Neurosurgery & Spine Consultants+3Genetic & Rare Diseases Center+3ScienceDirect+3
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: December 22, 2025.
